Relevance of Positron Emission Tomography (PET) in Oncology

Weber, Wolfgang; Avril, Norbert; Schwaiger, Markus

doi:10.1007/s000660050022

Cited by 133 publications

(65 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Today, 18 F-FDG PET has grown to be an important tool in the diagnostic management of patients with a variety of malignant tumors (10,11,(28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Differentiation of Malignant and Benign Cardiac Tumors Using ¹⁸F-FDG PET/CT

Rahbar

Seifarth²,

Schäfers³

et al. 2012

J Nucl Med

234

108

View full text Add to dashboard Cite

In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy and metastatic spread is of major interest to stratify patients and to select and monitor therapies. In the diagnostic work-up, morphologic imaging modalities such as echocardiography or magnetic resonance tomography offer information on, for example, size, invasiveness, and vascularization. However, preoperative assessment of malignancy may be unsatisfactory. The aim of this study was to evaluate the diagnostic value of 18 F-FDG PET and the incremental diagnostic value of an optimized CT score in this clinical scenario. Methods: 18 F-FDG PET/CT scans (wholebody imaging with low-dose CT) of 24 consecutive patients with newly diagnosed cardiac tumors were analyzed (11 men, 13 women; mean age 6 SD, 59 6 13 y). The maximum standardized uptake values (SUV max ) of the tumors were measured. Patients were divided into 2 groups: benign cardiac tumors (n 5 7) and malignant cardiac tumors (n 5 17) (cardiac primaries [n 5 8] and metastases [n 5 9]). SUV max was compared between the 2 groups. Results were compared with contrast-enhanced CT, using standardized criteria of malignancy. Histology served as ground truth. Results: Mean SUV max was 2.8 6 0.6 in benign cardiac tumors and significantly higher both in malignant primary and in secondary cardiac tumors (8.0 6 2.1 and 10.8 6 4.9, P , 0.01). Malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%), after a cutoff with high sensitivity (SUV max of 3.5) was chosen to avoid false-negatives. Morphologic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%). Both false-positive and false-negative decisions in morphology could be corrected in all but 1 case using a metabolic threshold with an SUV max of 3.5. In addition, extracardiac tumor manifestations were detected in 4 patients by whole-body 18 F-FDG PET/CT. Conclusion: 18 F-FDG PET/ CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors.

show abstract

“…Today, 18 F-FDG PET has grown to be an important tool in the diagnostic management of patients with a variety of malignant tumors (10,11,(28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

“…Overall, there is a correlation between the glucose accumulation in tumor tissue and the presence of malignancy, although exceptions are known (11,29,30,32,33). However, 18 F-FDG PET has not yet been systematically evaluated for the characterization of cardiac tumors.…”

Section: Discussionmentioning

confidence: 99%

Differentiation of Malignant and Benign Cardiac Tumors Using ¹⁸F-FDG PET/CT

Rahbar

Seifarth²,

Schäfers³

et al. 2012

J Nucl Med

234

108

View full text Add to dashboard Cite

show abstract

“…There have been more than 30 publications since 1998 reporting the use of PET for TVD in brain tumours (reviewed in [16,[20][21][22]32]). This work has been largely driven by the central role that imaging plays in the diagnosis of brain tumours and by the limitations of CT and MRI for imaging this site.…”

Section: Brain Tumoursmentioning

confidence: 99%

Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments

Price

Green²

2011

BJR

View full text Add to dashboard Cite

ABSTRACT. In an era in which it is possible to deliver radiation with high precision, there is a heightened need for enhanced imaging capabilities to improve tumour localisation for diagnostic, planning and delivery purposes. This is necessary to increase the accuracy and overall efficacy of all types of external beam radiotherapy (RT), including particle therapies. Positron emission tomography (PET) has the potential to fulfil this need by imaging fundamental aspects of tumour biology. The key areas in which PET may support the RT process include improving disease diagnosis and staging; assisting tumour volume delineation; defining tumour phenotype or biological tumour volume; assessment of treatment response; and in-beam monitoring of radiation dosimetry. The role of PET and its current developmental status in these key areas are overviewed in this review, highlighting the advantages and drawbacks.

show abstract

“…Enhanced glucose metabolism can be used to detect not only primary tumors but also recurrences and metastases. Numerous studies prove the diagnostic benefits of PET for various tumor entities and especially brain and pulmonary tumors, pancreatic masses and lymphomas [2]. PET has advantages over conventional staging methods in the locoregional lymph node staging of HNO tumors, breast cancer and malignant melanomas and in the mediastinal staging of bronchial carcinomas or prior to the resection of local recurrences or singular liver metastases of colorectal tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Whereas sonography, computed tomography (CT) and magnetic resonance imaging (MRI) provide above all predominantly morphological information, positron emission tomography (PET) permits functional characterization and visualization of (onco)biological processes, above all the noninvasive determination of regional metabolic activity [1, 2]. …”

Section: Introductionmentioning

confidence: 99%